Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

442993

registered interest
date	06/01/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions he has had with the National Council for Care Excellence on the development of a clinical guideline for pancreatic cancer; and if he will make a statement.
tabling member constituency	South Down
tabling member printed	Ms Margaret Ritchie
uin	21210
answer	answer is ministerial correction date of answer 14/01/2016 answer text <p>NHS England has asked the National Institute for Health and Care Excellence to develop a clinical guideline on the diagnosis and management of pancreatic cancer. The draft scope consultation is currently in progress and the anticipated publication date for the clinical guideline is January 2018.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/01/2016 13:12:12 answering member 4020 label Biography information for George Freeman
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

418049

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NHS England on how the survival rates for pancreatic cancer are reflected in assessments of new treatments for that disease.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9823
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>We have had no such discussions.</p><p> </p><p> </p><p> </p><p>NHS England assesses new cancer drugs for inclusion on the national Cancer Drugs Fund (CDF) list in accordance with its CDF Standard Operating Procedures, which are available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/cdf-sop/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/cdf-sop/</a></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 14:43:49 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

167507

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that the treatment for pancreatic cancer listed by the Cancer Drugs Fund will continue to be made available to patients on the NHS.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	216794
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br></p><p> </p><p>We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 15:04:29 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma

164385

registered interest
date	24/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to increase investment in pancreatic cancer research in the UK.
tabling member constituency	Foyle
tabling member printed	Mark Durkan
uin	215620
answer	answer is ministerial correction date of answer 27/11/2014 answer text <p>My hon. Friend the Parliamentary Under-Secretary of State for Public Health (Jane Ellison) has met recently with my hon. Friend the Member for Lancaster and Fleetwood (Eric Ollerenshaw) to discuss pancreatic cancer research and the report by the All Party Parliamentary Group (APPG) on Pancreatic Cancer and will write to the APPG shortly with comments on the report’s recommendations.</p><p> </p><p> </p><p> </p><p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health including pancreatic cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The available funding for all topic areas including pancreatic cancer is subject to future allocation of the Department’s research and development budget. A budget figure for 2015-16 will be set later this year.</p><p> </p><p> </p><p> </p><p>The NIHR is funding a £2 million five-year programme of research to understand the reasons why cancer diagnosis may be delayed, and to consider new designs for testing for cancer. The programme is a partnership between the Universities of Bristol, Cambridge, Bangor, Durham, Oxford, Exeter, the NIHR and Bristol NHS Clinical Commissioning Group. The programme objectives are to design and test new service pathways to cancer diagnosis which are based on sound medical evidence, make efficient use of resources and take full account of patients' views. The programme includes a study of factors influencing patient appraisal of symptoms and associations with cancer diagnosis. Participants in this study have been referred by their general practitioner to hospital for further investigation of symptoms suggestive of pancreatic, lung, or colorectal cancer.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 215621 215640 215641 question first answered 27/11/2014 17:15:52 answering member 4020 label Biography information for George Freeman
tabling member	1594 label Biography information for Mark Durkan

164386

registered interest
date	24/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will commission early diagnosis research projects specific to pancreatic cancer.
tabling member constituency	Foyle
tabling member printed	Mark Durkan
uin	215621
answer	answer is ministerial correction date of answer 27/11/2014 answer text <p>My hon. Friend the Parliamentary Under-Secretary of State for Public Health (Jane Ellison) has met recently with my hon. Friend the Member for Lancaster and Fleetwood (Eric Ollerenshaw) to discuss pancreatic cancer research and the report by the All Party Parliamentary Group (APPG) on Pancreatic Cancer and will write to the APPG shortly with comments on the report’s recommendations.</p><p> </p><p> </p><p> </p><p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health including pancreatic cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The available funding for all topic areas including pancreatic cancer is subject to future allocation of the Department’s research and development budget. A budget figure for 2015-16 will be set later this year.</p><p> </p><p> </p><p> </p><p>The NIHR is funding a £2 million five-year programme of research to understand the reasons why cancer diagnosis may be delayed, and to consider new designs for testing for cancer. The programme is a partnership between the Universities of Bristol, Cambridge, Bangor, Durham, Oxford, Exeter, the NIHR and Bristol NHS Clinical Commissioning Group. The programme objectives are to design and test new service pathways to cancer diagnosis which are based on sound medical evidence, make efficient use of resources and take full account of patients' views. The programme includes a study of factors influencing patient appraisal of symptoms and associations with cancer diagnosis. Participants in this study have been referred by their general practitioner to hospital for further investigation of symptoms suggestive of pancreatic, lung, or colorectal cancer.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 215620 215640 215641 question first answered 27/11/2014 17:15:52 answering member 4020 label Biography information for George Freeman
tabling member	1594 label Biography information for Mark Durkan

164392

registered interest
date	24/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will review the Government's funding for pancreatic cancer research following the recommendations of the report, Pancreatic Cancer Research: A roadmap to change, published by the All Party Parliamentary Group on Pancreatic Cancer.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	215640
answer	answer is ministerial correction date of answer 27/11/2014 answer text <p>My hon. Friend the Parliamentary Under-Secretary of State for Public Health (Jane Ellison) has met recently with my hon. Friend the Member for Lancaster and Fleetwood (Eric Ollerenshaw) to discuss pancreatic cancer research and the report by the All Party Parliamentary Group (APPG) on Pancreatic Cancer and will write to the APPG shortly with comments on the report’s recommendations.</p><p> </p><p> </p><p> </p><p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health including pancreatic cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The available funding for all topic areas including pancreatic cancer is subject to future allocation of the Department’s research and development budget. A budget figure for 2015-16 will be set later this year.</p><p> </p><p> </p><p> </p><p>The NIHR is funding a £2 million five-year programme of research to understand the reasons why cancer diagnosis may be delayed, and to consider new designs for testing for cancer. The programme is a partnership between the Universities of Bristol, Cambridge, Bangor, Durham, Oxford, Exeter, the NIHR and Bristol NHS Clinical Commissioning Group. The programme objectives are to design and test new service pathways to cancer diagnosis which are based on sound medical evidence, make efficient use of resources and take full account of patients' views. The programme includes a study of factors influencing patient appraisal of symptoms and associations with cancer diagnosis. Participants in this study have been referred by their general practitioner to hospital for further investigation of symptoms suggestive of pancreatic, lung, or colorectal cancer.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 215620 215621 215641 question first answered 27/11/2014 17:15:52 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

164393

registered interest
date	24/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the recommendations in the report of the All Party Parliamentary Group on Pancreatic Cancer, Pancreatic Cancer Research: A roadmap to change.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	215641
answer	answer is ministerial correction date of answer 27/11/2014 answer text <p>My hon. Friend the Parliamentary Under-Secretary of State for Public Health (Jane Ellison) has met recently with my hon. Friend the Member for Lancaster and Fleetwood (Eric Ollerenshaw) to discuss pancreatic cancer research and the report by the All Party Parliamentary Group (APPG) on Pancreatic Cancer and will write to the APPG shortly with comments on the report’s recommendations.</p><p> </p><p> </p><p> </p><p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health including pancreatic cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The available funding for all topic areas including pancreatic cancer is subject to future allocation of the Department’s research and development budget. A budget figure for 2015-16 will be set later this year.</p><p> </p><p> </p><p> </p><p>The NIHR is funding a £2 million five-year programme of research to understand the reasons why cancer diagnosis may be delayed, and to consider new designs for testing for cancer. The programme is a partnership between the Universities of Bristol, Cambridge, Bangor, Durham, Oxford, Exeter, the NIHR and Bristol NHS Clinical Commissioning Group. The programme objectives are to design and test new service pathways to cancer diagnosis which are based on sound medical evidence, make efficient use of resources and take full account of patients' views. The programme includes a study of factors influencing patient appraisal of symptoms and associations with cancer diagnosis. Participants in this study have been referred by their general practitioner to hospital for further investigation of symptoms suggestive of pancreatic, lung, or colorectal cancer.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 215620 215621 215640 question first answered 27/11/2014 17:15:53 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

101416

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make an assessment of the effect of the National Institute for Health and Care Excellence's health technology appraisals on pancreatic cancer research.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	212353
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>We have made no such assessment.</p><p> </p><p> </p><p> </p><p>The National Institute for Health Research is investing £6.5 million over five years to 2017 in the Liverpool Pancreas Biomedical Research Unit. This unit is working in partnership with industry and leading research institutions to develop new treatments and diagnostic strategies for pancreatic cancer, so advancements in science can lead to benefits for patients.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:38:12 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

101428

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will assess the effect of the National Institute for Health and Care Excellence's three month end of life threshold on the appraisal of treatments for advanced pancreatic cancer.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	212326
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>I refer the hon. Member to my answer of 15 October 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-questions-answers/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=209582" target="_blank">209582</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/11/2014 17:15:00 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

101431

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make an assessment of the National Institute for Health and Care Excellence's technology appraisal criteria in relation to the provision of new treatments for patients with pancreatic cancer.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	212359
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>We have made no such assessment. The National Institute for Health and Care Excellence is an independent body and is responsible for the development of its methods and processes, which it periodically updates in consultation with stakeholders.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/11/2014 17:22:16 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin